FindMyKOL
Clinical trialNCT03266003CompletedInterventional

An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment

NCT03266003 is an interventional trial sponsored by Centers for Disease Control and Prevention. As of 21 Nov 2026, it is completed. It studies Adherence, Medication, Adherence, Patient and 2 more conditions. The registry lists an enrollment of 216 participants at 4 sites in 1 country. The registry lists a start date of 19 Jul 2017 and a primary completion date of 10 Jan 2020.

SponsorCenters for Disease Control and Prevention →Enrollment216Adherence, MedicationAdherence, PatientDrug-resistant TuberculosisTuberculosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03266003
FieldValue
Registry IDNCT03266003
StatusCompleted
Study typeInterventional trial
Lead sponsorCenters for Disease Control and Prevention
Enrollment216
Registered sites4
Countries1
ConditionsAdherence, Medication, Adherence, Patient, Drug-resistant Tuberculosis and Tuberculosis
Start19 Jul 2017
Primary completion10 Jan 2020
Study completion31 Dec 2020
Last update posted2 Jul 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a U.S.-based, 1 site (with 4 clinical settings), randomized controlled trial (with funding from the Centers for Disease Control and Prevention's (CDC) Antibiotic Resistance Solutions Initiative) that will be implemented to evaluate traditional directly observed therapy (DOT) and electronic forms of DOT (eDOT) for tuberculosis (TB) treatment. The trial will assess whether eDOT that employs electronic communication methods, such as video via computer or cellphone, is a non-inferior approach to monitor TB treatment adherence, compared to traditional in-person DOT (ipDOT), in which a trained person is in the physical presence of patients as anti-TB drugs are ingested. ipDOT is the single best intervention proven to be successful when it comes to TB patients' adherence to therapy (which reduces risk of acquired drug resistance). However, ipDOT is resource intensive and many times challenging to facilitate in-person. If eDOT is found to be non-inferior to ipDOT, health departments and other clinicians might be able to provide eDOT to certain populations of TB patients in a more flexible and potentially cost-saving manner.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Joseph Burzynski, MD, MPH

    New York City DOHMH, Bureau of Tuberculosis Control

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States4 sites
  • Fort Greene Chest Center

    Brooklyn

  • Corona Chest Center

    Jackson Heights

  • Washington Heights Chest Center

    New York

  • Morrisania Chest Center

    The Bronx

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 4 sitesNY4MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT03266003

Each answer restates registry values shown on this page.

What is NCT03266003?

NCT03266003 is an interventional trial sponsored by Centers for Disease Control and Prevention. It studies Adherence, Medication, Adherence, Patient and 2 more conditions.

Who leads NCT03266003?

The registry names Joseph Burzynski, MD, MPH (principal investigator, New York City DOHMH, Bureau of Tuberculosis Control) as the overall official.

Where does NCT03266003 run?

The registry lists 4 sites in 1 country. Every site with a stated country is in one country: United States.

When did NCT03266003 end?

The registry lists a primary completion date of 10 Jan 2020 and a study completion date of 31 Dec 2020. The sponsor last updated the record on 2 Jul 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.